If you are trying to investigate protein:protein interactions inside cells, you know how important physiologically relevant results are. If you overload your cells with fusion constructs, your protein interactions may not actually reflect what is going on in the cell, and if your BRET energy donor and acceptor do not have sufficiently separated spectra, you can […]
The proper assay in drug development can help prevent failures in clinical trials. Learn about cell-based assays that help ensure success in drug development.
In the opening remarks of our second annual Targeted Protein Degradation Symposium, Tom Livelli, VP of Life Sciences Products & Services at Promega, posed a question to the attendees: “What do you want to be able to do today that you can’t?” This aspirational question set the tone for an event where building connections to […]
Model organisms are essential tools in the pursuit of understanding biological processes, elucidating the mechanisms of diseases, and developing potential treatments and therapies. Use of these organisms in scientific research has paved the way for groundbreaking discoveries across various fields of biology. In particular, non-mammalian models can be valuable due to characteristics such as rapid […]
Mitogen-activated protein kinases (MAPKs) are a large family of proteins that regulate diverse cellular functions in eukaryotes, including gene expression, proliferation, differentiation and apoptosis (1). MAPK signaling pathways typically include three sequentially activated kinases, and these pathways are triggered in response to extracellular stimuli, such as cytokines, mitogens, growth factors and oxidative stress (1). Ultimately, […]
Traditional approaches for protein degrader compound screening like Western blotting can be laborious, time consuming and cannot be streamlined with automation. By implementing a high-throughput, automated workflow that uses our CRISPER/Cas9 knock-in cell lines, live-cell bioluminescent assays and sensitive GloMax® Discover microplate readers, our custom assay services offer protein degradation profiling at an accelerated rate. […]
On September 20, more than 60 scientists from across North America convened at Promega Madison for our first Targeted Protein Degradation Symposium. For two days, speakers shared their most recent advances in this exciting field. “What has really stood out for me is the collective energy, the openness, the willingness of people to share their […]
“What I’ve learned in science is that we don’t do things alone. Everything is connected,” says Marcos da Silva Regueira Neto. Marcos is a post-doctoral research at the Federal University of Pernambuco in Recife, Brazil. His project is part of a large interdisciplinary study, so he is no stranger to collaboration and welcomes opportunities to […]
For cancers that have proven challenging to target with traditional therapies, one emerging option is an approach called synthetic lethality. Synthetic lethality arises when inactivation of two gene products together lead to cell death but where inactivation of one does not (1, 2). Targeting a gene that is synthetic lethal to a cancer-related mutation creates […]
In late May 2022, Promega invited the nine finalists for the Promega Brazil Young Researcher Award to present their work at a Student Research Symposium on the Promega Madison campus. The Brazil Young Researcher Award program was created to acknowledge exceptional work by Brazilian students utilizing Promega products in their research. These student researchers were […]
